Answers are grounded in this paper and cite their sources.
2002 GUIDELINES FOR THE USE OF ANTIMICROBIAL AGENTS IN NEUTROPENIC PATIENTS WITH CANCER [Hughes WT et al. CID 2002:34:730] This is the updated IDSA guidelines with the emphasis on the following points: Definition: Fever is defined as a single oral temp of 38.3°C × 1 or 38.0°C for over one hour. Neutropenia is defined as an ANC <500/mm3 or <1000/mm3 with a predicted decrease to <500/mm3. Evaluation for vancomycin need: 1) suspected catheter-related infection; 2) colonization with a penicillin or cephalosporin-resistant S. pneumoniae or MRSA; 3) positive blood cultures for GP bacteria prior to identification; or 4) hypotension. Assessment for possible oral antibiotic treatment: Patients at low risk for complications may often be treated with oral antibiotics if there is no focus of infection and lack of findings for systemic infection such as rigors or hypotension. If outpatient treatment is to be used, there must be access to medical care 24/7. Factors supporting low risk are a ANC exceeding 100/mm3, absolute monocyte count exceeding 100/ mm3, normal chest x-ray, normal renal and hepatic tests, neutropenia less than 7 days, malignancy in remission, temperature peak less than 39°, early evidence of marrow recovery, and none of the following: IV catheter site infection, neurologic or mental status changes, appearance of illness, abdominal pain or comorbidity. Antibiotic selection Low risk, oral treatment: ciprofloxacin plus amoxicillin-clavulanate. Low risk, IV therapy: cefepime, ceftazidime or carbapenem High risk with no need for vancomycin: monotherapy (see number 2) or dual therapy: aminoglycoside plus either an antipseudomonal penicillin, cefepime, ceftazidime or carbapenem. High risk and vancomycin needed: vancomycin plus cefepime, ceftazidime or carbapenem plus/minus aminoglycoside. Modifications of therapy based on response at 3–5 days Response and pathogen defined: adjust therapy based on pathogen. Response and no pathogen identified: oral therapy should be continued. IV therapy may be changed to oral ciprofloxacin plus amoxicillin-clavulanate after 48 hours Persistent fever at 3 days and no change in patient condition: continue same antibiotics, but consider discontinuing vancomycin if there is no clear need for it. Persistent fever at 3–5 days and progressive disease: change antibiotic regimen depending on the initial regimen. This includes the addition of vancomycin if it was not initially used and there are criteria for it, or consideration of discontinuing vancomycin if it was included in the initial regimen. Persistent fever at days 5–7: consider antifungal agent such as amphotericin B, lipid amphotericin B (no more effective, but reduced toxicity), or fluconazole. Fluconazole is acceptable at an institution where Aspergillus and azole-resistant Candida infections are uncommon, where fluconazole was not used as prophylaxis, and when there is no evidence of pulmonary disease or sinusitis. Recent reviews have not shown clear advantages in efficacy for empiric use of amphotericin B, lipid amphotericin, itraconazole, or fluconazole. Antibiotic discontinuation: Low risk patients may have antibiotics discontinued when they are afebrile 5–7 days. If the ANC increases above 500/mL, stop antibiotics at 4–5 days. If there is persistent fever at day 3 and persistent ANC <500/mm3, continue antibiotics for 2 weeks and reassess. Antiviral drugs: not recommended unless there is laboratory clinical support for use. Granulocyte transfusions: not recommended. G-CSF or GM-CSF: not recommended for routine use, but may be considered if there is an expected long delay in marrow recovery and those with documented infections who do not respond to antibiotics. Prophylaxis in neutropenic patients without fever: TMP-SMX is sometimes recommended for PCP regardless of neutropenia. There are good data supporting efficacy of prophylaxis with TMP-SMX, quinolones, fluconazole and itraconazole for reducing the number of infectious complications of neutropenia, but the Panel recommends against this prophylaxis due to the concerns for antibiotic resistance and the failure of these studies to show reduction in mortality.
No takes yet. Share an insight, caveat, or question.
A 2002 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: